BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

BAY14-2222 Continuous Infusion in Surgeries

Phase 3

Completed

Conditions: Hemophilia

Interventions: Drug: Kogenate (BAY14-2222)

First Posted Date: 2008-02-01

Last Posted Date: 2010-04-13

Lead Sponsor: Bayer

Target Recruit Count: 15

Registration Number: NCT00606060

Long-term Extension From RCC Phase II (11515)

Phase 2

Completed

Conditions: Carcinoma, Renal Cell

Interventions: Drug: Sorafenib (Nexavar, BAY43-9006)

First Posted Date: 2008-01-04

Last Posted Date: 2013-12-13

Lead Sponsor: Bayer

Target Recruit Count: 95

Registration Number: NCT00586495

Phase III Study of Sorafenib in Patients With Renal Cell Carcinoma (RCC)

Phase 3

Completed

Conditions: Carcinoma, Renal Cell

Interventions: Drug: Sorafenib (Nexavar, BAY43-9006)

First Posted Date: 2008-01-04

Last Posted Date: 2014-04-16

Lead Sponsor: Bayer

Target Recruit Count: 39

Registration Number: NCT00586105

BAY14-2222 Prophylaxis and Joint Function Improvement (Adults)

Phase 4

Completed

Conditions: Hematologic Disease
Hemophilia A

Interventions: Drug: Kogenate (BAY14-2222)

First Posted Date: 2008-01-04

Last Posted Date: 2014-11-02

Lead Sponsor: Bayer

Target Recruit Count: 20

Registration Number: NCT00586521

Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients

Phase 3

Completed

Conditions: Venous Thromboembolism

Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939)
Drug: Enoxaparin
Drug: Enoxaparin placebo
Drug: Rivaroxaban placebo

First Posted Date: 2007-12-12

Last Posted Date: 2016-09-15

Lead Sponsor: Bayer

Target Recruit Count: 8101

Registration Number: NCT00571649

Locations: 🇦🇷
Sanatorio Mitre, Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina
🇨🇦
CHUM - Hopital Notre-Dame, Montreal, Quebec, Canada
🇨🇦
Hotel Dieu-Grace Hospital, Windsor, Ontario, Canada

and more 10 locations

SH T00186 in the Treatment of Primary Dysmenorrhea

Phase 3

Completed

Conditions: Primary Dysmenorrhea

Interventions: Drug: YAZ (SH T00186D)

First Posted Date: 2007-12-07

Last Posted Date: 2014-10-29

Lead Sponsor: Bayer

Target Recruit Count: 223

Registration Number: NCT00569244

Study to Investigate the Effect of the A1 Agonist Capadenoson on Ventricular HR in Patients With Persistent or Permanent Atrial Fibrillation.

Phase 2

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Capadenoson (BAY68-4986)

First Posted Date: 2007-12-06

Last Posted Date: 2014-10-29

Lead Sponsor: Bayer

Target Recruit Count: 28

Registration Number: NCT00568945

A Clinical Study in Children and Adolescents With Mild to Moderate Atopic Dermatitis

Phase 4

Completed

Conditions: Mild to Moderate Atopic Dermatitis

Interventions: Device: Zarzenda
Drug: Elidel

First Posted Date: 2007-12-06

Last Posted Date: 2015-02-18

Lead Sponsor: Bayer

Target Recruit Count: 80

Registration Number: NCT00568412

Locations: 🇩🇪
Klinik und Poliklinik fuer Dermatologie, Universtitaetsklinikum, Bonn, Germany

Efficacy and Safety of Two Flexible Extended Regimens of BAY86-5300 (SH T00186D) in Comparison With the Conventional Regimen of YAZ

Phase 3

Completed

Conditions: Contraception
Ovulation Inhibition
Contraceptives, Oral

Interventions: Drug: EE20/DRSP (BAY86-5300)
Drug: EE20/DRSP (YAZ, BAY86-5300)

First Posted Date: 2007-12-04

Last Posted Date: 2014-03-12

Lead Sponsor: Bayer

Target Recruit Count: 1887

Registration Number: NCT00567164

Efficacy and Safety of Oral Dehydroepiandrosterone as a Concomitant Therapy to Oral Contraceptives in Women Complaining of Reduced Libido

Phase 2

Completed

Conditions: Libido

Interventions: Drug: Dehydroepiandrosterone, BAY86-5314
Drug: Placebo

First Posted Date: 2007-12-03

Last Posted Date: 2014-12-02

Lead Sponsor: Bayer

Target Recruit Count: 100

Registration Number: NCT00566384

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy